美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

上海醫藥ADR

7.60

0.0000

成交量：1.00

成交額：6.88

市值：56.31億

市盈率：9.43

高：7.60

開：7.60

低：7.60

收：7.60

52周最高：8.32

52周最低：6.39

股本：7.41億

流通股本：3.65億

量比：0.01

換手率：NaN%

股息：0.30

股息率：3.91%

每股收益(TTM):0.8063

每股收益(LYR):0.8419

淨資產收益率：7.91%

總資產收益率：2.15%

市淨率：0.51

市盈率(LYR):9.03

資料載入中...

總覽公司新聞資訊公告

上海市經信委：在上海好模型不缺算力，好應用不缺語料，好產品不缺芯片

上海醫藥：芪苓顆粒獲得臨床試驗批准通知書

格隆汇资讯

上海醫藥B023細胞注射液臨床試驗獲批

中信建投：腦機接口有望打開萬億市場空間需發掘國家政策支持和具有真實需求「真腦機」

上海生物醫藥產業併購基金完成3單投資

上海醫藥(02607)：硫酸羥氯喹片獲得菲律賓藥品註冊證書

智通财经网

研報掘金丨中郵證券：維持上海醫藥「買入」評級，看好創新業務驅動成長

流感陽性率接近45%！抗流感概念反覆活躍，產業鏈機會一覽

腾讯自选股

上海醫藥兩款藥品通過仿製藥一致性評價

上海醫藥(02607)：醋酸艾司利卡西平片的ANDA獲得美國FDA批准上市

智通财经网

從121.9到126：上海重點產業國際競爭力指數六年間持續提升

更「陽光」更惠民！國家「團購」藥品為就醫減負健康保障更加「可及+可靠」

上海醫藥出海突破：耗時四年，替格瑞洛片成功打入美國市場

上海醫藥：枸櫞酸託法替布緩釋片獲得批准生產

格隆汇资讯

全國中成藥第四批集採啓動醫療機構報量

上海醫藥集團股份有限公司等嘧啶環類化合物、其中間體、其藥物組合物及其應用專利完成登記（醫藥化學專利快訊）

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SHPMY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SHPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SHPMY\",,,,,undefined,":{"symbol":"SHPMY","market":"US","secType":"STK","nameCN":"上海醫藥ADR","latestPrice":7.6,"timestamp":1773667801774,"preClose":7.6,"halted":0,"volume":1,"delay":15,"changeRate":0,"floatShares":365061763,"shares":740922171,"eps":0.806273,"marketStatus":"已收盤","change":0,"latestTime":"03-16 09:30:01 EDT 延時","open":7.6,"high":7.6,"low":7.6,"amount":6.875,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.806273,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1773734400000},"marketStatusCode":5,"adr":0,"adrRate":5,"exchange":"PINK LIMITED","adjPreClose":7.6,"volumeRatio":0.010438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SHPMY\",,,,,undefined,":{"symbol":"SHPMY","floatShares":365061763,"roa":"2.15%","roe":"7.91%","lyrEps":0.841928,"volumeRatio":0.010438,"shares":740922171,"dividePrice":0.297473,"high":7.6,"amplitude":0,"preClose":7.6,"low":7.6,"week52Low":6.39,"pbRate":"0.51","psRate":"0.14","week52High":8.32,"institutionHeld":0,"latestPrice":7.6,"eps":0.806273,"divideRate":0.039141,"volume":1,"delay":15,"ttmEps":0.806273,"open":7.6,"prevYearClose":8.23,"prevWeekClose":7.6,"prevMonthClose":7.07,"prevQuarterClose":8.23,"fiveDayClose":7.6,"twentyDayClose":7.07,"sixtyDayClose":8.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SHPMY\",params:#limit:5,,,undefined,":[{"date":"2025-12-31","symbol":"SHPMY","amount":0.084937,"announcedDate":"2025-12-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"上海医药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-23","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-02-23"},{"date":"2025-07-17","symbol":"SHPMY","amount":0.202369,"announcedDate":"2025-06-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-17","defaultRemindTime":1752759000000,"name":"上海医药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-09","payableDate":"2025-07-17","currency":"USD","dateTimestamp":1752724800000,"payDate":"2025-09-09"},{"market":"US","date":"2025-03-27","symbol":"SHPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"","actualEps":null},{"date":"2024-09-19","symbol":"SHPMY","amount":0.0562,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-19","defaultRemindTime":1726752600000,"name":"上海医药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-12","payableDate":"2024-09-19","currency":"USD","dateTimestamp":1726718400000,"payDate":"2024-11-12"},{"market":"US","date":"2024-08-26","symbol":"SHPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1724644800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SHPMY\",market:\"US\",,,undefined,":[{"executeDate":"2016-07-13","recordDate":"2016-07-15","paymentDate":"2016-09-12","value":0.198416,"currency":"USD"},{"executeDate":"2019-07-11","recordDate":"2019-07-12","paymentDate":"2019-09-09","value":0.237205,"currency":"USD"},{"executeDate":"2020-07-15","recordDate":"2020-07-16","paymentDate":"2020-09-08","value":0.245893,"currency":"USD"},{"executeDate":"2021-07-14","recordDate":"2021-07-15","paymentDate":"2021-09-13","value":0.293406,"currency":"USD"},{"executeDate":"2023-07-17","recordDate":"2023-07-18","paymentDate":"2023-09-12","value":0.421212,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SHPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5714,"hold":0.2857,"sell":0.1429,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.2857,"analysts":7,"updateTime":1757736000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SHPMY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609461095","title":"上海市經信委：在上海好模型不缺算力，好應用不缺語料，好產品不缺芯片","url":"https://stock-news.laohu8.com/highlight/detail?id=2609461095","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609461095?lang=zh_tw&edition=fundamental","pubTime":"2026-02-07 12:48","pubTimestamp":1770439680,"startTime":"0","endTime":"0","summary":"近期上海多家AI企业上市，上海也提出加速人形机器人等创新产品突破产业规模化发展瓶颈。在上海，好模型不缺算力，好应用不缺语料，好产品不缺芯片。上海拥有全国近10%的算力，运营全国首个语料公共服务平台，推出138款备案大模型，实现多款智算芯片突破。《上海市经信委：在上海好模型不缺算力，好应用不缺语料，好产品不缺芯片》栏目主编：张骏文字编辑：曹飞","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2026-02-07/doc-inhkykzi4217183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4535","159813","00807","161631","BK4588","BK4585","SHPMY","02607","601607"],"gpt_icon":0},{"id":"2607707197","title":"上海醫藥：芪苓顆粒獲得臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2607707197","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607707197?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 16:20","pubTimestamp":1769674855,"startTime":"0","endTime":"0","summary":"格隆汇1月29日丨上海医药(601607.SH)公布，公司下属正大青春宝药业有限公司（简称“青春宝”）自主研发的“芪苓颗粒”（称“该项目”）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，芪苓颗粒处方源自杭州市中医院的临床验方。人用经验研究表明本品可缓解患者持续的关节肿痛症状，减少痛风急性发作次数；药效学试验表明本品与降尿酸化学药物联用可增强降尿酸效果，同时具有减轻肾脏病理损伤、保护肾功能的作用。该项目由青春宝自主研发，拥有核心知识产权。截至本公告披露日，该项目已累计投入研发费用约1,142万元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129162135a6bace52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129162135a6bace52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SHPMY","BK4175"],"gpt_icon":0},{"id":"2605145976","title":"上海醫藥B023細胞注射液臨床試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2605145976","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605145976?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 18:55","pubTimestamp":1768906510,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 王寅浩 宋雨盈）1月20日，上海医药发布公告称，公司下属上海医药集团生物治疗技术有限公司自主研发的“B023细胞注射液”收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展不可手术的经标准治疗失败的、无有效治疗方式的局部晚期或转移性实体瘤的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120185825a440bec2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120185825a440bec2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SHPMY","BK4175"],"gpt_icon":0},{"id":"2601868644","title":"中信建投：腦機接口有望打開萬億市場空間 需發掘國家政策支持和具有真實需求「真腦機」","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601868644?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 11:27","pubTimestamp":1767670058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，脑机接口升级为十五五产业战略，多重政策强力支持下，产业落地有望提速，建议重视投资机遇。脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来看若能实现增强人、并与AI和机器人融合，有望打开万亿市场空间。在投资方向选择方面，非侵入式和侵入式脑机接口无优劣之分，但需发掘国家政策支持和具有真实需求的“真脑机”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099","03347","LU1046422090.SGD","LU0052750758.USD","02359","LU2045819591.USD","SHPMY","LU2242644610.SGD","06978","09926","01177","BK1161","BK1576","01801","LU2125910500.SGD","02269","BK1141","LU0708995583.HKD","00013","BK1574","BK1583","02607","06160","LU0320764599.SGD"],"gpt_icon":0},{"id":"2595655337","title":"上海生物醫藥產業併購基金完成3單投資","url":"https://stock-news.laohu8.com/highlight/detail?id=2595655337","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595655337?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 08:45","pubTimestamp":1767055524,"startTime":"0","endTime":"0","summary":"记者获悉，从2025年3月设立至今，上海生物医药产业并购基金已完成三单投资，9个月时间已完成34%投资额。作为上海市国资基金矩阵中的重要组成部分，上海生物医药产业并购基金备受关注。2025年3月，上海生物医药产业并购基金正式宣告成立，首期规模50亿元，由上实集团旗下上实资本作为基金管理人。目前，上海生物医药产业并购基金已完成的3单投资，一是协助上海医药收购上海和黄，二是战略入股微创医疗，三是入股康华生物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230085626a487e60b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230085626a487e60b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00853","BK4175","SHPMY"],"gpt_icon":0},{"id":"2591643915","title":"上海醫藥(02607)：硫酸羥氯喹片獲得菲律賓藥品註冊證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643915","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643915?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 17:38","pubTimestamp":1765791500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上海上药中西制药有限公司生产的硫酸羟氯喹片收到菲律宾食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。1999年12月，上药中西的硫酸羟氯喹片在国内获批上市，并于2021年12月通过了仿制药一致性评价。本次硫酸羟氯喹片获得菲律宾食品药品监督管理局的药品注册批文，标志着公司具备了在菲律宾市场销售该药品的资格，对公司拓展海外市场带来积极影响，并积累了宝贵的经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215174008a44d88e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215174008a44d88e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SHPMY","BK4175"],"gpt_icon":0},{"id":"2590353543","title":"研報掘金丨中郵證券：維持上海醫藥「買入」評級，看好創新業務驅動成長","url":"https://stock-news.laohu8.com/highlight/detail?id=2590353543","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590353543?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 13:38","pubTimestamp":1765431532,"startTime":"0","endTime":"0","summary":"格隆汇12月11日｜中邮证券研报指出，上海医药商业板块稳健增长，Q3减值影响利润，看好创新业务驱动成长。2025Q1-3公司创新药业务实现销售收入407亿元，同比增长超过25%；进口总代业务实现销售收入276亿元，同比增长超过14%；器械大健康业务实现销售收入339.88亿元，同比增长超过4%。截至2025年9月30日，公司提交临床试验申请获得受理及进入后续临床试验阶段的新药管线共计57项，包括创新药管线45项。维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211133906a441a38c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211133906a441a38c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4175","SHPMY","02607"],"gpt_icon":0},{"id":"2588777090","title":"流感陽性率接近45%！抗流感概念反覆活躍，產業鏈機會一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777090","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777090?lang=zh_tw&edition=fundamental","pubTime":"2025-12-01 13:56","pubTimestamp":1764568560,"startTime":"0","endTime":"0","summary":"12月1日，抗流感概念反复活跃，海王生物触及涨停，粤万年青涨超12%，广济药业、亨迪药业、特一药业、金石亚药、新华制药跟涨。消息面上，11月27日，中国疾病预防控制中心发布的《全国急性呼吸道传染病哨点监测情况》显示，流感阳性率接近45%，整体进入中流行水平，部分省份已达高流行水平。光大证券表示，近期流感疫情上升态势明显，可能引发社会公众和市场关注度的提升，从而带动防治和检测流感产品的需求增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201134631a4c4f93d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201134631a4c4f93d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4175","SHPMY"],"gpt_icon":0},{"id":"2582246385","title":"上海醫藥兩款藥品通過仿製藥一致性評價","url":"https://stock-news.laohu8.com/highlight/detail?id=2582246385","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582246385?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 18:20","pubTimestamp":1762770017,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 王寅浩 宋雨盈）11月10日，上海医药发布公告称，公司下属上海上药新亚药业有限公司收到国家药品监督管理局颁发的《药品补充申请批准通知书》，注射用头孢呋辛钠、注射用氨曲南通过仿制药质量和疗效一致性评价。公告显示，注射用头孢呋辛钠适用于治疗呼吸道感染、耳鼻喉感染、泌尿系感染等疾病中特定微生物敏感菌株引起的感染，最早于1978在英国、意大利等国家上市；注射用氨曲南适用于治疗尿路（复杂和单纯的）、下呼吸道感染等敏感革兰氏阴性菌引起的感染，最早于1984年在意大利上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018203297600a9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018203297600a9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4175","SHPMY"],"gpt_icon":0},{"id":"2582219385","title":"上海醫藥(02607)：醋酸艾司利卡西平片的ANDA獲得美國FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2582219385","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582219385?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 17:38","pubTimestamp":1762767526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，上海医药集团股份有限公司下属上海上药中西制药有限公司 收到美国食品药品监督管理局的通知，其关于醋酸艾司利卡西平片的简略新药申请已获得最终批准上市。2018年1月，上药中西就该药品向美国FDA提出ANDA申请，于2020年6月获得该药品四个规格的ANDA暂时批准，并于近日获得最终批准上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110174111a6ef2fe7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110174111a6ef2fe7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4175","SHPMY"],"gpt_icon":0},{"id":"2582286840","title":"從121.9到126：上海重點產業國際競爭力指數六年間持續提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2582286840","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582286840?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 15:23","pubTimestamp":1762759425,"startTime":"0","endTime":"0","summary":"《2024-2025上海重点产业国际竞争力指数报告》认为，上海在此领域应进一步深化智能工厂建设和供应链协同，推广高度自动化的生产模式，以巩固和提高产业效率。自2018年以来，上海社会科学院与上海市商务委员会携手，持续发布《上海重点产业国际竞争力报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110152349975fb186&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110152349975fb186&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1163","BK1607","02607","00981","BK1614","02196","SHPMY","BK1610","BK1526"],"gpt_icon":1},{"id":"2581110340","title":"更「陽光」更惠民！國家「團購」藥品為就醫減負 健康保障更加「可及+可靠」","url":"https://stock-news.laohu8.com/highlight/detail?id=2581110340","media":"央视网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581110340?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 21:51","pubTimestamp":1762437060,"startTime":"0","endTime":"0","summary":"本次药品集采规则调整更“阳光”更惠民，引导市场良性竞争，为医药产业健康发展营造良好环境。第十一批药品集采对规则进行再升级，每一项调整都更加紧扣临床需求和药品质量，“阳光”规则让集采更惠民，在差比价计算方式上，适度向小规格的口服溶液、注射剂等儿童适宜剂型倾斜，激励企业保障供应，集采还进一步完善防范围标措施，既体现充分竞争尽显市场活力，又引导企业科学立项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106215301a48d9892&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106215301a48d9892&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02607","SHPMY","BK4175"],"gpt_icon":0},{"id":"2581901108","title":"上海醫藥出海突破：耗時四年，替格瑞洛片成功打入美國市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2581901108","media":"瑞财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581901108?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 18:04","pubTimestamp":1762423456,"startTime":"0","endTime":"0","summary":"财中社11月6日电上海医药 发布公告，公司下属常州制药厂有限公司收到美国食品药品监督管理局的通知，其关于替格瑞洛片的简略新药申请已获得最终批准上市。该药品用于急性冠脉综合征患者，降低血栓性心血管事件的发生率。常州制药厂于2021年5月向美国FDA提出该药品的ANDA申请，并于近期获得批准。目前，已有多家企业在美国上市了该药品的仿制药。2025年前三季度，上海医药实现收入2150.72亿元，归母净利润51.47亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106180421a6e5a5e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106180421a6e5a5e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SHPMY","BK4175"],"gpt_icon":0},{"id":"2581110830","title":"上海醫藥：枸櫞酸託法替布緩釋片獲得批准生產","url":"https://stock-news.laohu8.com/highlight/detail?id=2581110830","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581110830?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 17:12","pubTimestamp":1762420328,"startTime":"0","endTime":"0","summary":"格隆汇11月6日丨上海医药(601607.SH)公布，公司下属上海上药中西制药有限公司(简称“上药中西”)的枸橼酸托法替布缓释片(简称“该药品”)收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2025S03257)，该药品获得批准生产。枸橼酸托法替布缓释片用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎。根据国家相关政策，按新注册分类获批仿制药的品种在医保支付及医疗机构采购等领域将获得更大的支持力度。因此上药中西的枸橼酸托法替布缓释片获得批准生产，有利于扩大该药品的市场份额，提升市场竞争力，同时为公司后续产品开展仿制药申报积累了宝贵的经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106171233a48cf747&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106171233a48cf747&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SHPMY","BK4175"],"gpt_icon":0},{"id":"2581701170","title":"全國中成藥第四批集採啓動醫療機構報量","url":"https://stock-news.laohu8.com/highlight/detail?id=2581701170","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581701170?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 14:20","pubTimestamp":1762410003,"startTime":"0","endTime":"0","summary":"湖北省医疗保障局近日发布通知，启动全国中成药联合采购联盟第四批集中采购的医疗机构数据填报工作，要求联盟地区组织辖区内医疗机构在规定时间内完成相关品种的采购量信息填报。目前仅开展医疗机构报量阶段，企业报名时间尚未明确。医疗机构需如实上报2024年实际采购量、价格及金额，并准确预估未来一年采购需求。孙跃武分析称，2024年中药材原料价格普遍回落，成本下降可能进一步推动中成药集采价格下行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110614261097577f3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110614261097577f3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SHPMY","BK4175"],"gpt_icon":0},{"id":"2575223143","title":"上海醫藥集團股份有限公司等嘧啶環類化合物、其中間體、其藥物組合物及其應用專利完成登記（醫藥化學專利快訊）","url":"https://stock-news.laohu8.com/highlight/detail?id=2575223143","media":"DoNews","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575223143?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 14:05","pubTimestamp":1760421903,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025-10-14，“嘧啶环类化合物、其中间体、其药物组合物及其应用”正式进入专利的公布阶段。申请人为上海医药集团股份有限公司，该项医药化学专利涉及KRAS突变体抑制及蛋白降解治疗技术领域。据专利信息显示，该化合物对KRAS突变体具有良好的抑制作用或蛋白降解作用，有望在肿瘤靶向治疗中实现突破性进展。发明人为李迪;段灵峻;浦小青;楼江松;霍国永;马星;夏广新。本发明公开了一种嘧啶环类化合物、其中间体、其药物组合物及其应用。该化合物为如式I所示的化合物，或它们药学上可接受的盐。本发明的化合物对KRAS突变体具有良好的抑制作用或蛋白降解作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014140549a45efc8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014140549a45efc8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","02607","BK1197","BK1161","BK1574","SHPMY"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}